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1 |  INTRODUCTION
Thalassemia's carrier screening programs are based on he-
matological parameters. However, some drawbacks mean 
not all mutations are detected. A clinical and genetic study 
of a HBB carrier is presented to show such a drawback. A 
family was referred to our center for genetic counseling. 
The pedigree was documented and the couple's hematolog-
ical indices and HbA2 level were measured. HBB and HBD 
genes were sequenced. In silico analyses was then performed. 
Microcytosis, hypochromia, mild anemia, and minor thalas-
semia were noted, and the woman's HbA2 level was 3.3%. 
All individuals were carriers of an HBB mutation. A codon 
82/83 mutation was found in the father, and the mother of the 
family was a carrier of an IVSII-1 (c.315 + 1G>A) mutation 
with MCH = 21.2pg and MCV = 96.6fL. The child was also 
carrier of IVS-1 with typical hematological indices. Given 
that HbA2 levels may vary, and some individuals may not 
be detected in screening programs; we considered the role of 
modifier variants. That is the HbA2 marker may be insuffi-
cient for detection of beta thalassemia trait even without iron 
deficiency, and thus, molecular genetic testing is important.
Carrier and couple screening programs are the most suc-
cessful way to diminish the incidence of thalassemia. Beta 
thalassemia is the most common cause of anemia world-
wide.1,2 The prevention of thalassemia has been investigated 
for many years in Iran. Between 1990 and 1995, a control 
and prevention of thalassemia pilot program was undertaken. 
One of the major aims was to reduce the birth of new cases 
of the major thalassemia. During this program, the number 
of affected births decreased from 1,300 to 300 people per 
year, that is, the disease was prevented in approximately 80% 
of cases.3 Briefly, to detect carriers MCV, MCH, and HbA2 
levels are screened in couples. If both members of the cou-
ple are detected as carriers, a molecular genetic diagnosis is 
recommended. Some people may have mild inherited anemia 
Received: 26 May 2020 | Revised: 7 December 2020 | Accepted: 13 December 2020
DOI: 10.1002/ccr3.3714  
C A S E  R E P O R T
HBB mutations and HbA2 level: Escaping the carrier screening 
programs
Ameneh Sharifi1,2 |   Nejat Mahdieh1,3
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
1Growth and Development Research Center, 
Tehran University of Medical Sciences, 
Tehran, Iran
2Premarital Counseling Center of Ilam 
University of Medical Sciences, Ilam, Iran
3Cardiogenetic Research Center, Rajaie 
Cardiovascular Medical and Research 
Center, Iran University of Medical 
Sciences, Tehran, Iran
Correspondence
Nejat Mahdieh, Cardiogenetic Research 
Center, Rajaei Cardiovascular Medical and 
Research Center, Iran University of Medical 





HbA2 level alone for beta thalassemia trait may not be accurate and reliable even 
without iron deficiency so molecular genetic testing is important and should be con-
sidered for some individuals.
K E Y W O R D S
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but HbA2 in normal range; sometimes these people are not 
identified in the screening process. In some cases, these indi-
viduals may have a complete deletion of the beta-globin gene 
cluster and if their husbands/wives have thalassemia trait, 
each pregnancy has a 25% chance of producing an affected 
child.
Different HBB mutations are found in different geograph-
ical areas. The highest incidence of the disease has been re-
ported in Asia, particularly in residents of the coastal areas 
of South and Southeast Asian countries and regions around 
the Mediterranean.1,4 More than 900 HBB mutations have 
been characterized in different populations worldwide (http://
www.hgmd.cf.ac.uk/). Several specific mutations (about 
5-10 types) predominate and have a unique pattern of dis-
tribution for each population; for example, the six common 
mutations: c.315  +  1G>A, c.477  +  5G>A, c.92  +  6T>C, 
c.112delT, frame shift c.27_28insG, and c.251delG are re-
sponsible for 90% of all mutant alleles in the Mediterranean 
region.5 Numerical studies document genotype-phenotype 
correlations of patients with thalassemia.5-7
As an accurate and reliable marker for beta thalassemia 
trait, HbA2 is usually measured; it is normally between 2.2% 
and 3.5%. HbA2, a tetramer of alpha- and delta-globin chains, 
has been used as a diagnostic indicator of the presence of 
beta thalassemia trait in recent years. A relative surplus of 
alpha-globin chains in beta thalassemia trait individuals in-
creases the formation alpha-delta dimer. In beta thalassemia 
trait, it is usually increased to more than 3.5%. HbA2 levels 
in β0 mutation carriers reportedly are higher than in carri-
ers of β+ mutations. Hematological parameters in carriers of 
the c.315 + 1G>A mutation are as follow: HbA2 = 4.75% 
- 5.55%, MCH = 18.7 - 20.5 pg, and MCV 62.1 - 77.9 fL 
(http://globin.bx.psu.edu/hbvar/ menu.html)8. But sometimes, 
HbA2 levels are not elevated. The most common cause of low 
levels of HbA2 in beta thalassemia trait patients is concom-
itant of alpha thalassemia. In addition, low levels of HbA2 
(usually between 35% and 40%) are observed in delta thal-
assemia, delta/beta thalassemia, and some delta-globin vari-
ants. Here, we report a Kurdish family with HBB mutation 
showing low level of HbA2 that passed the screening pro-
gram and investigate the molecular basis of their condition.
2 |  MATERIALS AND METHODS
2.1 | Clinical history and presentation
A couple (27-year-old woman and a 28-year-old man) with 
Kurd ethnicity was referred for counseling. The woman's he-
matological indices showed microcytosis, hypochromia, and 
mild anemia (Table 1) but the level of HbA2 was within the 
normal range (HbA2 = 3.3%). Based on the national program 
of thalassemia control guidelines,3 iron deficiency was diag-
nosed in the woman and iron therapy started. After 3 months 
of treatment with folic acid and ferrous sulfate, no change 
was observed in hematological indices.
2.2 | Genetic testing
A signed informed consent form was obtained; and five mL 
of peripheral blood was taken from the couple. DNA was 
extracted from using the conventional salting out method. 
The concentration of DNA was quantified using a spectro-
photometer (NanoDrop ND2000c; Thermo Scientific). The 
coding and noncoding regions of the HBB and HBD genes 
were amplified and sequenced using forward and reverse 
primers [available upon request]. The polymerase chain 
Factor Unit Father Mother Son Normal range
RBC millions/μL 6.5 5.0 5.0 4.7-6.1
Hb g/dL 13.1 10.7 11.3 F:12-16
M:14-18
MCV fL 64.0 69.6 64 80-96
MCH pg 20.2 21.2 20 27-31
MCHC gm% 31.6 30.5 31 33-37
HbA % 92.5 90.1 91.5 >97
HbA2 % 5.8 3.3 5.8 1.5-3.5
HbF % 1.7 6.6 2.7 0.0-0.9
HCT % 41.5 35.1 36.7 F:36-45
M:41-51
SLI % 1292.8 1475.52 1280 < 1530
Abbreviations: Hb, Hemoglobin; HbA, Hemoglobin A; HbA2, Hemoglobin A2; HbF, Fetal Hemoglobin; 
HCT, Hematocrit; MCH, Mean Cell Hemoglobin; MCHC, Mean Corpuscular Hemoglobin Concentration; 
MCV, Mean Corpuscular Volume; RBC, Red Blood Cell; SLI, Shine and Lal index.
T A B L E  1  Hematological factors in this 
family
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reaction (PCR) was carried out using a conventional protocol 
published elsewhere.8 Briefly, each reaction contains 50 ng 
of genomic DNA, 1 unit of Taq-DNA polymerase, 0.2 mM 
of dNTP, 0.2  mM of each primer, 1.5  mM of Mgcl2, and 
1X PCR buffer. Thirty PCR cycles were as follows 95°C for 
45 seconds, 67°C for 35 seconds, 72°C for 100 seconds, and 
72°C for 10  minutes. The PCR products were directly se-
quenced by a BigDye termination method and use of a se-
quencing analyzer ABI 3500 (PE Applied Biosystems).
3 |  RESULTS
Hematological indices in the woman were HbA2 = 3.3 and 
HbF = 6.6, and in the man were HbA2 = 5.8 and HbF = 1.7 
(Table 1, Figure 1). Only in HBB gene, c.315 + 1G>A and 
c.251delG mutations were detected in the woman and the 
man, respectively. After genetic counseling and receiving 
required information about the risks of having children, pre-
natal diagnosis and; possible future difficulties, they decided 
to progress to marriage. During the pregnancy, the fetus was 
checked for HBB mutation. Fortunately, the fetus was not 
affected; it was diagnosed as a carrier of IVSII-1 (G > A). 
Their child was born. Hematological indices of the son are 
indicated in Table 1. The level of Hb A2 was 5.8%. These 
two mutations were examined using HbVar Database in dif-
ferent populations (Table 2).
4 |  DISCUSSION
Here is the family were not detected in the standard screening 
system. They presented having HBB mutations but normal 
HbA2 levels. IVS II-1(G > A), c.315 + 1G>A, is a β0 type of 
mutation. In a few HBB mutation carriers with normal delta-
globin genes, HbA2 shows a normal level.9,10 In iron-defi-
cient carriers of HBB mutation, a lower than expected HbA2 
has been reported 11,12; in a study conducted 444 people with 
HBB carrier, the mean HbA2 was 5.3% and 5.6% in iron-
deficient and non–iron-deficient individuals.13 Nevertheless, 
other investigations have explained no significant impact 
of iron deficiency on the HbA2 level in beta thalassemia 
carriers.14,15
In the studied couple, hematological findings suggested 
that the man was a carrier but the woman was affected by iron 
deficiency-mediated anemia (Table 1). The SLI (Shine and 
Lal index) was less than 1530 for both individuals. Due to lack 
of response to treatment after two months in the woman, the 
HBB gene was sequenced and only a mutation c.315 + 1G>A 
was detected. Changes of hematological factors for carriers 
of the mutation are known (Table 3). In a study conducted 
in the Ilam population, the mean average of HbA2 was equal 
to 5.4% in carriers of this mutation.16 But HbA2 was only 
3.3% in this woman, that is, it is borderline and in the normal 
range. This mutation leads to inactivation of donor splice site 
and disruption in normal splicing and processing of mRNA. 
The mutation was found for the first time in the Arab popu-
lations. c.315 + 1G>A is the most common mutation in Iran, 
Kuwait, and Yemen with a frequency of 26.47%, 29%, and 
26.67%, respectively (http://globin.bx.psu.edu/hbvar/ menu.
html).17 The mutation shows a high frequency in most parts 
of Iran especially in central, western, and northern regions. 
Some mutations have an ethnic specific frequency; for ex-
ample, a large deletion mutation in GJB6 is absent in Iranian 
populations18 or different mutations of CYP21A2 have a dif-
ferent distributions in our population.19,20
The high HbF value (6.6%) of the woman may be due to 
a marked anemia. Furthermore, the gamma chains tend to 
compete with delta chains; therefore, there is a reduction in 
the real HbA2 values that the beta zero thalassemia carrier 
would be expected to have. Phenotypic variability seen in this 
family may be due to modifier factors. Modifier genes have 
been reported in several genetic diseases.21,22 As known, the 
HBB has a central role in oxygen transport from the lung to 
the various peripheral tissues. In thalassemia, a number of 
genes have been reported as modifiers.23-25
The c.251delG (deletion of G at codons 82/83, AAGGGC) 
was reported for the first time in two Azerbaijanian patients.26 
But it is most prevalent in Czechoslovakian patients accord-
ing to the HBVar database (7.53%). This variant is catego-
rized as a β0 mutation.
A functional CACCC box at HBD promoter acts as the 
principal cause of the high activity of the HBD promoter, 
that is, absence of this box provides the binding site for the 
Krüppel-like factor 1 (KLF1) which acts as a transcription 
factor.27,28 It is predicted to modify pathological states of 
alpha-hemoglobin excess in diseases such as beta thalas-
semia.29 In addition, other proteins such as cytoglobin may 
have a role during conditions of oxidative stress and in intra-
cellular oxygen storage or transfer. The normal level of HbA2 
in the woman is probably due to a modifying variant in these 
genes. Further studies are recommended to find the variants 
of modifying genes; for example, the regulatory sequences of 
HBD and quantitative analyses of this gene could be done. 
F I G U R E  1  HBB mutations in the studied family. N: normal 
allele
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So identifying the modifier genes is required for prediction of 
phenotype and may be helpful to interpret the unexpected re-
sults. Hence, molecular genetic testing should be performed 
to accurately diagnose beta thalassemia carriers.
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